Clinical Trials
2 trialsNCT06597734 2026-05-20
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT04953312 2026-03-12
CALPRO
Assistance Publique - Hôpitaux de Paris
Phase NA Withdrawn